Literature DB >> 19535780

Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study.

Gregory T Armstrong1, Qi Liu, Yutaka Yasui, Sujuan Huang, Kirsten K Ness, Wendy Leisenring, Melissa M Hudson, Sarah S Donaldson, Allison A King, Marilyn Stovall, Kevin R Krull, Leslie L Robison, Roger J Packer.   

Abstract

BACKGROUND: Adult survivors of childhood central nervous system (CNS) malignancies are at high risk for long-term morbidity and late mortality. However, patterns of late mortality, the long-term risks of subsequent neoplasms and debilitating medical conditions, and sociodemographic outcomes have not been comprehensively characterized for individual diagnostic and treatment groups.
METHODS: We collected information on treatment, mortality, chronic medical conditions, and neurocognitive functioning of adult 5-year survivors of CNS malignancies diagnosed between 1970 and 1986 within the Childhood Cancer Survivor Study. Using competing risk framework, we calculated cumulative mortality according to cause of death and cumulative incidence of subsequent neoplasms according to exposure and dose of cranial radiation therapy (RT). Neurocognitive impairment and socioeconomic outcomes were assessed with respect to dose of CNS radiotherapy to specific brain regions. Cumulative incidence of chronic medical conditions was compared between survivors and siblings using Cox regression models. All tests of statistical significance were two-sided.
RESULTS: Among all eligible 5-year survivors (n = 2821), cumulative late mortality at 30 years was 25.8% (95% confidence interval [CI] = 23.4% to 28.3%), due primarily to recurrence and/or progression of primary disease. Patients who received cranial RT of 50 Gy or more (n = 813) had a cumulative incidence of a subsequent neoplasm within the CNS of 7.1% (95% CI = 4.5% to 9.6%) at 25 years from diagnosis compared with 1.0% (95% CI = 0% to 2.3%) for patients who had no RT. Survivors had higher risk than siblings of developing new endocrine, neurological, or sensory complications 5 or more years after diagnosis. Neurocognitive impairment was high and proportional to radiation dose for specific tumor types. There was a dose-dependent association between RT to the frontal and/or temporal lobes and lower rates of employment, and marriage.
CONCLUSIONS: Survivors of childhood CNS malignancies are at high risk for late mortality and for developing subsequent neoplasms and chronic medical conditions. Care providers should be informed of these risks so they can provide risk-directed care and develop screening guidelines.

Entities:  

Mesh:

Year:  2009        PMID: 19535780      PMCID: PMC2704230          DOI: 10.1093/jnci/djp148

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   11.816


  48 in total

Review 1.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Authors:  T A Gooley; W Leisenring; J Crowley; B E Storer
Journal:  Stat Med       Date:  1999-03-30       Impact factor: 2.373

2.  Dose reconstruction for therapeutic and diagnostic radiation exposures: use in epidemiological studies.

Authors:  Marilyn Stovall; Rita Weathers; Catherine Kasper; Susan A Smith; Lois Travis; Elaine Ron; Ruth Kleinerman
Journal:  Radiat Res       Date:  2006-07       Impact factor: 2.841

3.  Reliability and validity of the Childhood Cancer Survivor Study Neurocognitive Questionnaire.

Authors:  Kevin R Krull; Gerard Gioia; Kirsten K Ness; Leah Ellenberg; Christopher Recklitis; Wendy Leisenring; Sujuan Huang; Marilyn Stovall; Leslie L Robison; Lonnie Zeltzer
Journal:  Cancer       Date:  2008-10-15       Impact factor: 6.860

4.  Health-related quality of life among child and adolescent survivors of childhood cancer.

Authors:  Kathy N Speechley; Maru Barrera; Amanda K Shaw; Howard I Morrison; Elizabeth Maunsell
Journal:  J Clin Oncol       Date:  2006-06-01       Impact factor: 44.544

5.  Mortality among 5-year survivors of cancer diagnosed during childhood or adolescence in British Columbia, Canada.

Authors:  Amy C MacArthur; John J Spinelli; Paul C Rogers; Karen J Goddard; Zenaida U Abanto; Mary L McBride
Journal:  Pediatr Blood Cancer       Date:  2007-04       Impact factor: 3.167

6.  An analysis of SEER data of increasing risk of secondary malignant neoplasms among long-term survivors of childhood brain tumors.

Authors:  Katia M Peterson; Cheng Shao; Robert McCarter; Tobey J MacDonald; Julianne Byrne
Journal:  Pediatr Blood Cancer       Date:  2006-07       Impact factor: 3.167

7.  Outcome analysis of childhood low-grade astrocytomas.

Authors:  Paul G Fisher; Tarik Tihan; Patricia T Goldthwaite; Moody D Wharam; Benjamin S Carson; Jon D Weingart; Michael X Repka; Kenneth J Cohen; Peter C Burger
Journal:  Pediatr Blood Cancer       Date:  2008-08       Impact factor: 3.167

8.  Survival and late mortality in long-term survivors of pediatric CNS tumors.

Authors:  E Brannon Morris; Amar Gajjar; James O Okuma; Yutaka Yasui; Dana Wallace; Larry E Kun; Thomas E Merchant; Maryam Fouladi; Alberto Broniscer; Leslie L Robison; Melissa M Hudson
Journal:  J Clin Oncol       Date:  2007-04-20       Impact factor: 44.544

9.  Characteristics of childhood cancer survivors predicted their successful tracing.

Authors:  Ann C Mertens; Roberta Sposato Walls; Leslie Taylor; Pauline A Mitby; John Whitton; Peter D Inskip; John D Potter; Leslie L Robison
Journal:  J Clin Epidemiol       Date:  2004-09       Impact factor: 7.407

10.  Utilization of special education services and educational attainment among long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.

Authors:  Pauline A Mitby; Leslie L Robison; John A Whitton; Michael A Zevon; Iris C Gibbs; Jean M Tersak; Anna T Meadows; Marilyn Stovall; Lonnie K Zeltzer; Ann C Mertens
Journal:  Cancer       Date:  2003-02-15       Impact factor: 6.921

View more
  160 in total

1.  Subsequent neoplasms in survivors of childhood central nervous system tumors: risk after modern multimodal therapy.

Authors:  Karen Tsui; Amar Gajjar; Chenghong Li; Deokumar Srivastava; Alberto Broniscer; Cynthia Wetmore; Larry E Kun; Thomas E Merchant; David W Ellison; Brent A Orr; Frederick A Boop; Paul Klimo; Jordan Ross; Leslie L Robison; Gregory T Armstrong
Journal:  Neuro Oncol       Date:  2014-11-13       Impact factor: 12.300

2.  Vocational services associated with competitive employment in 18-25 year old cancer survivors.

Authors:  David Strauser; Michael Feuerstein; Fong Chan; Juan Arango; Elizabeth da Silva Cardoso; Chung-Yi Chiu
Journal:  J Cancer Surviv       Date:  2010-04-07       Impact factor: 4.442

3.  Parent and teacher ratings of attention during a year-long methylphenidate trial in children treated for cancer.

Authors:  Kelli L Netson; Heather M Conklin; Jason M Ashford; Lisa S Kahalley; Shengie Wu; Xiaoping Xiong
Journal:  J Pediatr Psychol       Date:  2010-11-19

4.  Engagement and experience with cancer-related follow-up care among young adult survivors of childhood cancer after transfer to adult care.

Authors:  Dava Szalda; Lisa Pierce; Wendy Hobbie; Jill P Ginsberg; Lauren Brumley; Monika Wasik; Yimei Li; Lisa A Schwartz
Journal:  J Cancer Surviv       Date:  2015-08-25       Impact factor: 4.442

5.  Low- and middle-income countries can reduce risks of subsequent neoplasms by referring pediatric craniospinal cases to centralized proton treatment centers.

Authors:  Phillip J Taddei; Nabil Khater; Bassem Youssef; Rebecca M Howell; Wassim Jalbout; Rui Zhang; Fady B Geara; Annelise Giebeler; Anita Mahajan; Dragan Mirkovic; Wayne D Newhauser
Journal:  Biomed Phys Eng Express       Date:  2018-02-07

6.  Blood-brain barrier-adapted precision medicine therapy for pediatric brain tumors.

Authors:  Bernard L Marini; Lydia L Benitez; Andrew H Zureick; Ralph Salloum; Angela C Gauthier; Julia Brown; Yi-Mi Wu; Dan R Robinson; Chandan Kumar; Robert Lonigro; Pankaj Vats; Xuhong Cao; Katayoon Kasaian; Bailey Anderson; Brendan Mullan; Benjamin Chandler; Joseph R Linzey; Sandra I Camelo-Piragua; Sriram Venneti; Paul E McKeever; Kathryn A McFadden; Andrew P Lieberman; Noah Brown; Lina Shao; Marcia A S Leonard; Larry Junck; Erin McKean; Cormac O Maher; Hugh J L Garton; Karin M Muraszko; Shawn Hervey-Jumper; Jean M Mulcahy-Levy; Adam Green; Lindsey M Hoffman; Katie Dorris; Nicholas A Vitanza; Joanne Wang; Jonathan Schwartz; Rishi Lulla; Natasha Pillay Smiley; Miriam Bornhorst; Daphne A Haas-Kogan; Patricia L Robertson; Arul M Chinnaiyan; Rajen Mody; Carl Koschmann
Journal:  Transl Res       Date:  2017-08-10       Impact factor: 7.012

7.  Long-term health-related quality of life in pediatric brain tumor survivors receiving proton radiotherapy at <4 years of age.

Authors:  Bree R Eaton; Saveli Goldberg; Nancy J Tarbell; Miranda P Lawell; Sara L Gallotto; Elizabeth A Weyman; Karen A Kuhlthau; David H Ebb; Shannon M MacDonald; Torunn I Yock
Journal:  Neuro Oncol       Date:  2020-09-29       Impact factor: 12.300

8.  Association between radiation dose to neuronal progenitor cell niches and temporal lobes and performance on neuropsychological testing in children: a prospective study.

Authors:  Kristin J Redmond; E Mark Mahone; Stephanie Terezakis; Omar Ishaq; Eric Ford; Todd McNutt; Lawrence Kleinberg; Kenneth J Cohen; Moody Wharam; Alena Horska
Journal:  Neuro Oncol       Date:  2013-01-14       Impact factor: 12.300

9.  Age-Dependent Cellular and Behavioral Deficits Induced by Molecularly Targeted Drugs Are Reversible.

Authors:  Joseph Scafidi; Jonathan Ritter; Brooke M Talbot; Jorge Edwards; Li-Jin Chew; Vittorio Gallo
Journal:  Cancer Res       Date:  2018-03-20       Impact factor: 12.701

10.  Hypothalamic-Pituitary Disorders in Childhood Cancer Survivors: Prevalence, Risk Factors and Long-Term Health Outcomes.

Authors:  Laura van Iersel; Zhenghong Li; Deo Kumar Srivastava; Tara M Brinkman; Kari L Bjornard; Carmen L Wilson; Daniel M Green; Thomas E Merchant; Ching-Hon Pui; Rebecca M Howell; Susan A Smith; Gregory T Armstrong; Melissa M Hudson; Leslie L Robison; Kirsten K Ness; Amar Gajjar; Kevin R Krull; Charles A Sklar; Hanneke M van Santen; Wassim Chemaitilly
Journal:  J Clin Endocrinol Metab       Date:  2019-12-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.